26.04.2022.Dr Mijomir Pelemiš rođen je 1949. godine u Šeheru. Završio je srednju medicinsku školu u Tuzli, a zatim Medicinski fakultet u Beogradu 1976. godine. U Institutu za infektivne i tropske bolesti radi od 1978. godine, a načelnik je odeljenja za kliničku farmakoterapiju, od njegovog osnivanja 1995. godine. U biografiji piše da je najveći deo svog radnog veka u Klinici posvetio ispitivanju bolesnika sa nejasnim febrilnim stanjem i modernoj antimikrobnoj terapiji.
Dr Pelemiš je izabran u zvanje redovnog profesora 2004. godine na Medicinskom fakultetu Univerziteta u Beogradu, a radi i kao profesor na Medicinskom fakultetu Univerziteta Istočno Sarajevo u Foči. Počasni je profesor bugarskog Medicinskog Univerziteta u Varni, piše u biografiji. Osnovao Jugoslovensko udruženje za antimikrobnu hemoterapiju (sada Srpsko udruženje za antimikrobnu hemoterapiju) 2002. godine, čiji je predsednik od osnivanja. Bio je direktor Klinike za infektivne i tropske bolesti u dva navrata – od 2001. do 2010. godine i od 2014 do 2015. godine.
Osim gorenavedenih informacija u biografiji objavljenoj na sajtu poliklinike Intertim piše da je dr Pelemiš član Udruženja za antimikrobnu hemoterapiju Jugoistočne Evrope, Internacionalnog udruženja za antimikrobnu hemoterapiju, upravnog odbora FESCI-a, Medicinske akademije Srpskog lekarskog društva, sekcije infektologa Srpskog lekarskog društva, Internacionalne medicinske asocijacije Bugarske, Internacionalnog uređivačkog odbora časopisa „International Journal of Antimicrobial Agents” i savetodavnog borda časopisa „Eurosurveillence”. Odlukom Vlade Srbije imenovan je za člana Kriznog štaba za suzbijanje zarazne bolesti kovid-19. Krajem 2020. godine odlikovan je ordenom Karađorđeve zvezde prvog stepena zbog doprinosa u borbi protiv virusa korona.
Analiza naučne produkcije korona influensera koju je sproveo FakeNews Tragač pokazuje da Mijomir Pelemiš u kategorizovanim časopisima ima 22 objavljena rada, od kojih jedan potpisuje kao prvi autor. Podaci iz tabele i sa spiska odnose se na period do kraja oktobra 2021. godine.
| Citati | Kategorija | |
| Popović, N., Stefanović-Budimkić, M., Mitrović, N., Urošević, A., Milošević, B., Pelemiš, M., … & Jovanović, D. (2013). The frequency of poststroke infections and their impact on early stroke outcome. Journal of Stroke and Cerebrovascular Diseases, 22(4), 424-429. | 63 | M22 |
| Fung, S., Kwan, P., Fabri, M., Horban, A., Pelemis, M., Hann, H. W., … & Gane, E. (2014). Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology, 146(4), 980-988. | 170 | M21a |
| Papa, A., Boźović, B., Pavlidou, V., Papadimitriou, E., Pelemis, M., & Antoniadis, A. (2002). Genetic detection and isolation of Crimean-Congo hemorrhagic fever virus, Kosovo, Yugoslavia. Emerging infectious diseases, 8(8), 852. | 176 | M21a |
| Fung, S., Kwan, P., Fabri, M., Horban, A., Pelemis, M., Hann, H. W., … & Gane, E. (2017). Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. Journal of hepatology, 66(1), 11-18. | 40 | M21a |
| Popovic, N., Korac, M., Nesic, Z., Milosevic, B., Urosevic, A., Jevtovic, D., … & Milosevic, I. (2015). Oral teicoplanin for successful treatment of severe refractory Clostridium difficile infection. The Journal of Infection in Developing Countries, 9(10), 1062-1067. | 15 | M23 |
| Dakić, Z., Pelemiš, M., Djurković-Djaković, O., Lavadinović, L., Nikolić, A., Stevanović, G., … & Pavlović, M. (2011). Imported malaria in Belgrade, Serbia, between 2001 and 2009. Wiener klinische Wochenschrift, 123(1), 15-19. | 12 | M22 |
| Dimitrijević, D., Ilić, D., Adrović, S. R., Šuljagić, V., Pelemiš, M., Stevanović, G., … & Grujićić, S. Š. (2016). Predictors of hospitalization and admission to intensive care units of influenza patients in Serbia through four influenza seasons from 2010/2011 to 2013/2014. Japanese journal of infectious diseases, JJID-2016. | 8 | M23 |
| Pelemiš, M., Stevanović, G., Lavadinović, L., Matić, S., Milošević, I., Korać, M., … & Prostran, M. (2013). A rare case of Candida parapsilosis endocarditis in a young healthy woman–case report. Journal of cardiothoracic surgery, 8(1), 1-5. | 9 | M23 |
| Jotić, A., Božić, D. D., Milovanović, J., Pavlović, B., Ješić, S., Pelemiš, M., … & Ćirković, I. (2016). Biofilm formation on tympanostomy tubes depends on methicillin-resistant Staphylococcus aureus genetic lineage. European Archives of Oto-Rhino-Laryngology, 273(3), 615-620. | 6 | M22 |
| Zec, S., Despotovic, A., Spurnic-Radovanovic, A., Milosevic, I., Jovanovic, M., Pelemis, M., & Stevanovic, G. (2016). Antimicrobial resistance in patients with urinary tract infections and the impact on empiric therapy in Serbia. The Journal of Infection in Developing Countries, 10(10), 1065-1072. | 7 | M23 |
| Radovanović-Spurnić, A. P., Stevanović, G., Dakić, Z., Ofori-Belić, I., Spurnić, I., & Pelemiš, M. (2015). Human subcutaneous dirofilariasis: Case report. Medicinski pregled, 68(7-8), 273-276. | 7 | M51 |
| Dakić, Z., Nielsen, H. V., Pavlović, M., Poluga, J., Stevanović, G., Lavadinović, L., … & Stensvold, C. R. (2016). Retrospective PCR-based species identification of Leishmania in two patients with visceral leishmaniasis in Serbia. JMM case reports, 3(5). | 4 | M23 |
| Stevanovic, G., Lavadinovic, L., Filipovic Vignjevic, S., Holt, R., Ilic, K., Berlanda Scorza, F., … & Flores, J. (2018). Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults. Human vaccines & immunotherapeutics, 14(3), 579-586. | 3 | M22 |
| Stevanovic, G., Obradovic, A., Ristic, S., Petrovic, D., Milenkovic, B., Mitrovic, D., … & Rathi, N. (2020). Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults. Therapeutic advances in vaccines and immunotherapy, 8, 2515135520925336. | 0 | M22 |
| Jovanović, M., Milošević, B., Dulović, O., Pelemiš, M., Stevanović, G., Tošić, T., … & Zervos, M. J. (2013). Molecular characterization of vancomycin-resistant enterococci in Serbia: Intensive care unit as the source. Acta microbiologica et immunologica Hungarica, 60(4), 433-446. | 3 | M23 |
| Fung, S., Fabri, M., Wong, F., Heathcoate, J., Gurel, S., Kwan, W. C. P., … & Hirsch10, K. R. (2011). Reduced bone mineral density derived from dual X-ray absorptiometry (DEXA) assessments in patients with chronic hepatitis B (CHB). Age (yrs), 48(20), 73. | 2 | M21 |
| Milosevic, I., Korac, M., Popovic, N., Lavadinovic, L., Urosevic, A., Milosevic, B., … & Stevanovic, G. (2018). Influenza A H1N1 virus infection among pregnant women in a tertiary hospital in Belgrade, Serbia. The Journal of Infection in Developing Countries, 12(05), 380-384. | 0 | M23 |
| Radovanović-Spurnić, A., Spurnić, I., Stevanović, G., Kosovac, O., & Pelemiš, M. (2015). Breast implant infection after radical mastectomy with Citrobacter koseri: Case report. Acta chirurgica Iugoslavica, 62(2), 61-64. | 0 | M51 |
| Bojić, I., Pavlović, M., Pelemiš, M., Đokić, M., & Begović, V. (2003). Significance of some factors in the pathogenesis of hemorrhagic fevers. Vojnosanitetski pregled, 60(4), 487-491. | 0 | M23 |
| Antic, D., Petrovic, N., Pelemis, M., Stevanovic, G., Perunicic, M., & Mihaljevic, B. (2013). ” Invisible” primary cutaneous diffuse large B-cell lymphoma, leg type, as a cause of fever of unknown origin. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 31(17), e276-9. | 4 | M21a |
| Fung, S., Kwan, P., Fabri, M., Horban, A., Pelemis, M., Husa, P., … & Gane, E. (2012). Efficacy and Safety of Tenofovir DF (TDF) in Chronic Hepatitis B Virus Infected Patients with Documented Lamivudine Resistance (LAM-R): 20. Hepatology, 56. | 17 | M21a |
| Fung, S., Hann, H. W., Elkhashab, M., Berg, T., Fabri, M., Horban, A., … & Gane, E. (2015). Long Term Efficacy and Safety of Tenofovir DF (TDF) in Chronic Hepatitis B Patients (CHB) with Documented Lamivudine Resistance (LAM-R): 5 Year Results From a Randomized, Controlled Trial: 2004. Hepatology, 62. | 4 | M21a |
